Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves Zylonta for large B-cell lymphoma – ADC Therapeutics

Written by | 8 May 2021

ADC Therapeutics announced that the FDA has approved Zylonta (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or… read more.

Progress seen in indolent lymphoma treatment, experts say

Written by | 14 Jan 2020

The majority of patients with follicular lymphoma (FL) have excellent results when treated with chemotherapy so — even with evolving understanding of disease biology and availability of a parade… read more.

The Dual Immunomodulation in Aggressive Lymphoma (DIAL) study

Written by | 14 Jan 2020

Professor Stephen Ansell (Rochester, USA) discusses the DIAL study

Updates from the UK at ASH

Written by | 14 Jan 2020

Dr Graham Collins (Oxford, UK) discusses real-world data from patients treated with CD19 CAR-T in England. He then reviews data presented on the risk of fracture following front-line R-CHOP… read more.

Experts explore questions in peripheral T cell lymphoma

Written by | 14 Jan 2020

Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.

Rituximab plus chemotherapy yields good results in younger HL patients

Written by | 14 Jan 2020

Using rituximab in combination with chemotherapy — tailored based on risk profile and response speed — produced good results in children, adolescents and young adults with classic Hodgkin lymphoma,… read more.

Immunotherapy drugs show promise in lymphoma

Written by | 14 Jan 2020

Dr Alison J.  Moskowitz (New York, USA) and Dr Graham Collins (Oxford, UK) review the long-term follow up data from brentuximabvedotin and nivolumab for R/R Hodgkin lymphoma Written by Thomas R. Collins

Pre-transplant salvage in Hodgkin lymphoma

Written by | 14 Jan 2020

Dr Alison J. Moskowitz (New York, USA) highlights the long-term follow up data for single-agent brentuximab vedotin as pre-transplant salvage. 

Study updates in Hodgkin lymphoma

Written by | 14 Jan 2020

Dr Wendy Osborne (Newcastle upon Tyne, UK) highlights data coming from the H10 and AHL2011 trials. She then reviews data presented on the long-term follow up of the HD14… read more.

Highlights from ASH 2019

Written by | 14 Jan 2020

The American Society of Hematology (ASH) Annual Meeting in 2019, held in Orlando, Florida, as usual gave interesting updates in the management of lymphoma.

Precision epigenetic therapy

Written by | 10 Sep 2019

“The genome can be thought of as the hardware driving a cell whereas the epigenome is more like the software – it is dynamic and erasable”, said Professor Ari… read more.

Integrating new cellular therapies

Written by | 10 Sep 2019

Prof Stephen Ansell (Rochester, USA) discusses how the new cellular technologies are being integrated into standard practice.Written by Esther Drain.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.